Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Prognostic Impact of Interim and Final PET in Primary Mediastinal Large B-Cell Lymphoma Treated with Intensive Etoposide-Based Therapy

Vít Procházka, MD, PhD, Lenka Henzlová, MD, Eva Buriánková, MD PhD, Zuzana Prouzová, MD, Ale Obr, MD, Martin Novák, Dr., Jiří Minařík, MD PhD, Karel Indrák, MD Prof., Tomá Papajík, MD PhD ass. prof.

Blood (2014) 124 (21): 1729.

https://doi.org/10.1182/blood.V124.21.1729.1729

Published: 2014

Journal Articles

Number of PD-1+/CD8+ Cells in Peripheral Blood of Patients with Lymphoma Reflects Tumor Burden, Lymphoma Subtype, Disease Phase and Is Significantly Higher Compared to Healthy Volunteers.

Vit Prochazka, M.D., Ph.D., Martin Novák, Dr., Zuzana Pikalova, Dr., Tomas Papajik, Dr., Ph.D., Karel Indrak, MD, Prof., Vladimir Divoky, Ph.D., ass. prof.

Blood (2012) 120 (21): 2670.

https://doi.org/10.1182/blood.V120.21.2670.2670

Published: 2012

Journal Articles

Programmed Death-1 Ligand Is Uniformly Expressed On Primary Mediastinal Diffuse Large B-Cell Lymphoma Cells with No Influence On Patient Survival.

Vit Prochazka, M.D., Ph.D., Tomas Papajik, Dr., Ph.D., Patrik Flodr, Dr., Pavla Latalova, Dr., Zuzana Prouzova, Dr., Radka Nedomova, Mgr., Marie Jarosova, Prof., Vladimir Divoky, Ph.D., ass. prof., Karel Indrak, MD, Prof.

Blood (2012) 120 (21): 2671.

https://doi.org/10.1182/blood.V120.21.2671.2671

Published: 2012

Journal Articles

Outcome of Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated with or without Rituximab

Heidi Mocikova, MD, PhD, Jozef Michalka, MD, Jan Koren, Pavla Stepankova, Alexander Wild, Ludek Raida, MD, Jana Markova, MD, Zdenek Kral, Marek Trneny, MD, Karel Indrak, MD, Prof., Jiri Mayer, M.D., PhD., Prof., Tomas Kozak, M.D., Ph.D.

Blood (2012) 120 (21): 4878.

https://doi.org/10.1182/blood.V120.21.4878.4878

Published: 2012

Journal Articles

EUTOS Score Is Also Valid in CML Patients Not Involved in Clinical Studies

Verena S Hoffmann, MA., Jiri Mayer, MD, Anna G. Turkina, MD, PhD, Andrzej Hellmann, MD, Karel Indrak, MD, Prof., Juan Luis Steegmann, MD, Andrey Zaritskey, MD, Adriana Colita, MD, Doris Lindoerfer, Dipl.-Inf., Michele Baccarani, MD

Blood (2012) 120 (21): 3759.

https://doi.org/10.1182/blood.V120.21.3759.3759

Published: 2012

NARROW

Prognostic Impact of Interim and Final PET in Primary Mediastinal Large B-Cell Lymphoma Treated with Intensive Etoposide-Based Therapy

Number of PD-1+/CD8+ Cells in Peripheral Blood of Patients with Lymphoma Reflects Tumor Burden, Lymphoma Subtype, Disease Phase and Is Significantly Higher Compared to Healthy Volunteers.

Programmed Death-1 Ligand Is Uniformly Expressed On Primary Mediastinal Diffuse Large B-Cell Lymphoma Cells with No Influence On Patient Survival.

Outcome of Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated with or without Rituximab

EUTOS Score Is Also Valid in CML Patients Not Involved in Clinical Studies

Email alerts

ASH Publications

American Society of Hematology

Prognostic Impact of Interim and Final PET in Primary Mediastinal Large B-Cell Lymphoma Treated with Intensive Etoposide-Based Therapy

Number of PD-1+/CD8+ Cells in Peripheral Blood of Patients with Lymphoma Reflects Tumor Burden, Lymphoma Subtype, Disease Phase and Is Significantly Higher Compared to Healthy Volunteers.

Programmed Death-1 Ligand Is Uniformly Expressed On Primary Mediastinal Diffuse Large B-Cell Lymphoma Cells with No Influence On Patient Survival.

Outcome of Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated with or without Rituximab

EUTOS Score Is Also Valid in CML Patients Not Involved in Clinical Studies

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only